A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless the context otherwise requires, all references in this Annual Report on Form 10-K to the “Company”, “Delcath”, “Delcath Systems”, “we”, “our”, and “us” refers to Delcath Systems, Inc., a Delaware corporation, incorporated in August 1988, and all entities included in our consolidated financial statements. Our corporate offices are located at 566 Queensbury Avenue, Queensbury, New York 12804. Our telephone number is (518) 743-8892 and our internet address is www.delcath.com. The information found on, or otherwise accessible through, our website is not incorporated by reference into, and does not form a part of, this Annual Report on Form 10-K. Company Overview We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 85M | 85M | 37M | - | - | - |
| Net Income | 2.7M | 2.7M | -26M | -48M | -37M | -26M |
| EPS | $0.07 | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| Free Cash Flow | 21M | 21M | -19M | -31M | -25M | -23M |
| ROIC | 0.0% | - | -38.4% | -183.9% | -189.5% | -114.9% |
| Gross Margin | 86.2% | 86.2% | 46.2% | - | - | - |
| Debt/Equity | 0.01 | 0.01 | 0.02 | 1.29 | -1.89 | 1.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 0 | - | -12M | -38M | -34M | -25M |
| Operating Margin | 0.0% | - | -33.4% | - | - | - |
| ROE | 2.4% | 3.0% | -38.4% | -302.2% | - | -214.6% |
| Shares Outstanding | 39M | 39M | 28M | 33M | 25M | 7M |
DELCATH SYSTEMS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
DELCATH SYSTEMS, INC. trades at 155.4x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 18.0x vs a median of 18.9x. The company's 5-year average gross margin is 66.2%. Total shareholder yield (buybacks) is 1.4%.
DELCATH SYSTEMS, INC. (DCTH) has a current P/E ratio of 155.4, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
DELCATH SYSTEMS, INC. (DCTH) has a 5-year average return on invested capital (ROIC) of -131.7%. This is below average and may indicate limited pricing power.
DELCATH SYSTEMS, INC. (DCTH) has a market capitalization of $420M. It is classified as a small-cap stock.
DELCATH SYSTEMS, INC. (DCTH) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.43%.
Based on historical P/E analysis, DELCATH SYSTEMS, INC. (DCTH) appears expensive. The current P/E of 155.4 is 936% above its historical median of 15.0.
DELCATH SYSTEMS, INC. (DCTH) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
DELCATH SYSTEMS, INC. (DCTH) reported annual revenue of $85 million in its most recent fiscal year, based on SEC EDGAR filings.
DELCATH SYSTEMS, INC. (DCTH) has a net profit margin of 3.2%. This is a modest margin.
DELCATH SYSTEMS, INC. (DCTH) generated $21 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
DELCATH SYSTEMS, INC. (DCTH) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
DELCATH SYSTEMS, INC. (DCTH) reported earnings per share (EPS) of $0.07 in its most recent fiscal year.
DELCATH SYSTEMS, INC. (DCTH) has a return on equity (ROE) of 3.0%. This indicates moderate shareholder returns.
DELCATH SYSTEMS, INC. (DCTH) has a 5-year average gross margin of 66.2%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for DELCATH SYSTEMS, INC. (DCTH), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DELCATH SYSTEMS, INC. (DCTH) has a book value per share of $2.88, based on its most recent annual SEC filing.